NCT00074308View on ClinicalTrials.gov

Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Recurrent MelanomaStage III MelanomaStage IV MelanomaUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

imatinib mesylate

Given orally

BIOLOGICAL

bevacizumab

Given IV

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

19104

Abramson Cancer Center of The University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00074308 - Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers | Biotech Hunter | Biotech Hunter